Share：
Share this content in WeChat
X
[Chinese][PDF]100077
• Clinical Article •
Diagnostic performance of MRI and CT for hepatocellular carcinoma less than 3 cm based on liver reporting and data system version 2018
JIANG Jian  WANG Wei  CUI Yunan  ZHANG Maowei  CHEN Dan  FANG Xin  LIU Ailian 

Cite this article as: Jiang J, Wang W, Cui YN, et al. Diagnostic performance of MRI and CT for hepatocellular carcinoma less than 3 cm based on liver reporting and data system version 2018[J]. Chin J Magn Reson Imaging, 2021, 12(9): 25-29, 44. DOI:10.12015/issn.1674-8034.2021.09.006.


[Abstract] Objective To investigate the diagnostic value of liver reporting and data system version 2018 (LI-RADS v2018) for diagnosing hepatocellular carcinoma (HCC) less than 3 cm between MRI and CT. Materials andMethods The data of total 73 patients with HCC less than 3 cm and liver cirrhosis induced by HBV confirmed by pathology from January 2009 to December 2020 were retrospectively analyzed. The CT and MRI features of the HCC lesion were analyzed and categorized according to the LI-RADS v2018. Then the lesions were classified and compared between CT and MRI. The accuracy of LI-RADS v2018 in the diagnosis of HCC were calculated and compared based on pathology.Results The recognition rate of "capsule" appearance in the major features of HCC was significant higher in MRI than that in CT (P＜0.001). The recognition rates of mild to restricted diffusion (86.3%) was more common than the other ancillary features of HCC in MRI, and mosaic architecture (25.0%) was more common than the other ancillary features of HCC in CT. In comparison of CT and MRI, statistically significant difference were found in the HCC lesions classified based on LI-RADS v2018 (P＜0.001). When adopting LR-4/5 as a predictor of HCC, the accuracy was increased for MRI compared with CT (P=0.046).Conclusions Based on LI-RADS v2018, the recognition rates of some HCC features and the accuracy of HCC were increased for MRI compared with CT.
[Keywords] hepatocellular carcinoma；liver reporting and data system version 2018；computerized tomography；magnetic resonance imaging

JIANG Jian   WANG Wei   CUI Yunan   ZHANG Maowei   CHEN Dan   FANG Xin   LIU Ailian*  

Department of Radiology, the First Affiliated Hospital of Dalian Medical University, Dalian 116000, China

Liu AL, E-mail: liuailian@dum.edu.cn

Conflicts of interest   None.

ACKNOWLEDGMENTS The Education Department of Liaoning Province Foundation (No. LZ2019047).
Received  2021-04-19
Accepted  2021-05-28
DOI: 10.12015/issn.1674-8034.2021.09.006
Cite this article as: Jiang J, Wang W, Cui YN, et al. Diagnostic performance of MRI and CT for hepatocellular carcinoma less than 3 cm based on liver reporting and data system version 2018[J]. Chin J Magn Reson Imaging, 2021, 12(9): 25-29, 44. DOI:10.12015/issn.1674-8034.2021.09.006.

[1]
Dimitroulis D, Damaskos C, Valsami S, et al. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world[J]. World J Gastroenterol, 2017, 23(29): 5282-5294. DOI: 10.3748/wjg.v23.i29.5282.
[2]
Yang J, Hainaut P, Gores G, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Review Gastroenterol Hepatol, 2019, 16(10): 589-604. DOI: 10.1038/s41575-019-0186-y.
[3]
Wang C, Wey K, Mo L, et al. Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma[J]. Asian Pac Cancer Prev, 2015, 16(9): 3595-3604. DOI: 10.7314/apjcp.2015.16.9.3595.
[4]
Elsayes K, Hooker J, Agrons M, et al. 2017 Version of LI-RADS for CT and MR imaging: an update[J]. Radiographics, 2017, 37(7): 1994-2017. DOI: 10.1148/rg.2017170098.
[5]
Ayuso C, Rimola J, Vilana R, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines[J]. Eur J Radiol, 2018, 101: 72-81. DOI: 10.1016/j.ejrad.2018.01.025.
[6]
Marrero J, Kulik L, Sirlin C, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2018, 68(2): 723-750. DOI: 10.1002/hep.29913.
[7]
Choi J, Cho H, Sun M, et al. Indeterminate observations (liver imaging reporting and data system category 3) on MRI in the cirrhotic liver: fate and clinical implications[J]. AJR American J Roentgenol, 2013, 201(5): 993-1001. DOI: 10.2214/ajr.12.10007.
[8]
Pomfret E, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States[J]. Liver Transplant, 2010, 16(3): 262-278. DOI: 10.1002/lt.21999.
[9]
American College of Radiology. LI-RADS Version 1.0 [EB/OL]. 2017, 4. https://www.acr.org/Quality-Safety/Resources/LIRADS/Archive.
[10]
American College of Radiology. LI-RADS v2014 [EB/OL]. 2017, 4. https://www.acr.org/Quality-Safety/Resources/LIRADS/LIRADS-v2014.
[11]
Ren A, Zhao P, Yang D, et al. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017[J]. J Magn Reson Imaging, 2019, 50(3): 746-755. DOI: 10.1002/jmri.26640.
[12]
Ocker M, Mayr C, Kiesslich T, et al. Immunmodulatory treatment strategies of hepatocellular carcinoma: from checkpoint inhibitors now to an integrated approach in the future[J]. Cancers, 2021, 13(7): DOI: 10.3390/cancers13071558.
[13]
Chaudhari V, Khobragade K, Bhandare M, et al. Management of fibrolamellar hepatocellular carcinoma[J]. Chin Clin Oncol, 2018, 7(5): 51. DOI: 10.21037/cco.2018.08.08.
[14]
Sheng RF, Zeng MS, Rao SX, et al. Comparison of MRI findings of small hepatocellular carcinoma and small intrahepatic mass-forming cholangiocarcinoma[J]. Chin J Radiol, 2014, 48(4): 288-293. DOI: 10.3760/cma.j.issn.1005-1201.2014.04.006.
[15]
Jeon S, Joo I, Lee D, et al. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging[J]. Eur Radiol, 2019, 29(1): 373-382. DOI: 10.1007/s00330-018-5605-x.
[16]
Yang CW, Jiang HY, Song B, et al. The diagnostic performance of version 2018 LI-RADS for hepatocellular carcinoma on Gd-EOB-DTPA enhanced MRI[J]. Chin J Radiol, 2019, (12): 1060-1064. DOI: 10.3760/cma.j.issn.1005-1201.2019.12.007.
[17]
Khanna G, Chavhan G, Schooler G, et al. Diagnostic Performance of LI-RADS Version 2018 for evaluation of pediatric hepatocellular carcinoma[J]. Radiology, 2021, 299(1): 190-199. DOI: 10.1148/radiol.2021203559.
[18]
Muramatsu Y, Nawano S, Takayasu K, et al. Early hepatocellular carcinoma: MR imaging[J]. Radiology, 1991, 181(1): 209-213. DOI: 10.1148/radiology.181.1.1653443.
[19]
Hanna R, Aguirre D, Kased N, et al. Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features[J]. Radiographics, 2008, 28(3): 747-769. DOI: 10.1148/rg.283055108.
[20]
Li BR, Zhang K, Yan XB, et al. The differential diagnostic value of LI-RADS v2018 based on MRI between hepatocellular carcinoma and other primary hepatic malignancy less than 3 cm[J]. Chin J Radiol, 2021, 55(02): 166-172. DOI: 10.3760/cma.j.cn112149-20200220-00206.
[21]
American College of Radiology. LI-RADS v2018 Core [EB/OL]. 2019, 2. https://www.acr.org/Clinical-Resources/Reporting-and-Data-SystemsLI-RADS/CT-MRI-LI-RADS-v2018.
[22]
Rosenkrantz A, Campbell N, Wehrli N, et al. New OPTN/UNOS classification system for nodules in cirrhotic livers detected with MR imaging: effect on hepatocellular carcinoma detection and transplantation allocation[J]. Radiology, 2015, 274(2): 426-433. DOI: 10.1148/radiol.14140069.
[23]
Wang K, Guo XC, Wang H, et al. Interreader agreement of multiphasic MDCT and unenhanced combined with enhanced MR imaging: a multicenter, intra-individual study based on LI-RADS v2014[J]. Radiol Pract, 2016, 31(04): 291-295.
[24]
Iavarone M, Viganò M, Piazza N, et al. Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance[J]. Ann Hepatol, 2019, 18(2): 318-324. DOI: 10.1016/j.aohep.2018.09.002.
[25]
Liu X, Jiang H, Chen J, et al. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis[J]. Liver Transplant, 2017, 23(12): 1505-1518. DOI: 10.1002/lt.24867.
[26]
Park M, Kim Y, Lee M, et al. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<=2.0 cm) in patients with hepatitis-induced liver cirrhosis[J]. Acta Radiol, 2013, 54(2): 127-136. DOI: 10.1258/ar.2012.120262.
[27]
An C, Kim M. Imaging features related with prognosis of hepatocellular carcinoma[J]. Abdom Radiol (NY), 2019, 44(2): 509-516. DOI: 10.1007/s00261-018-1758-y.

PREV Study on the value of liver-specific contrast agent MRI abbreviated sequence in screening small hepatocellular carcinoma in high-risk population
NEXT Tentative discussion on cardiac magnetic resonance in differentiating common types of cardiac amyloidosis
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn